"Given the severity and extent of the weakness in global commodities including the demand for coal as described above, it is not possible or indeed reasonable for the directors to advise with any confidence the likely time frame for ATC’s clinical advancement nor progression of its two pre-clinical, early stage drugs.
In the meantime the Company has been actively exploring a number of business development opportunities capable of extending the Company's business and restoring shareholder value pending a recovery in commodities. A number of potential targets have been identified and are currently undergoing preliminary due diligence. Pending completion of such preliminary due diligence, there is no certainty that any transaction will proceed."
can be long now.
AVX Price at posting:
0.8¢ Sentiment: None Disclosure: Held